Combined Technologies Create Basis for Joint Development of
Multi-Functional Nanotechnology Platforms
EATONTOWN, N.J., April 10, 2014 (GLOBE NEWSWIRE) -- American CryoStem Corporation (OTCQB:CRYO), a biotechnology developer, marketer and licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has filed its first jointly-owned patent application with its research partners at Rutgers University titled, "Nanoparticle-Mediated Synthetic Transcription Factor for Enhanced Gene Regulation and Cell Differentiation."
In May 2013, American CryoStem entered into a series of agreements with research scientists at Rutgers, The State University of New Jersey, including KiBum Lee, PhD, Professor of Chemistry & Chemical Biology. American CryoStem's initial collaboration with Dr. Lee, focused on utilizing American CryoStem's proprietary ATCELL ™ (Adipose-Derived Stem Cells (ADSCs)) and patented, ACSelerate ™ (animal serum free), GMP grade, cell culture and differentiation mediums to enhance Dr. Lee's multi-functional nanotechnology and biomaterial platforms ( NanoScript ™) that are capable of directing adipose-derived stem cell differentiation. The combined technologies create a Regenerative Medicine platform which can be used to treat a wide range of degenerative diseases and orthopedic injuries.
NanoScript ™ is a platform technology, based on the combination of nanosized particles including gold and other unique FDA approved biomaterials, with a series of predetermined peptides and binding domains in specific ratios to create a synthetic transcription factor capable of differentiating hADSCs without introducing a virus or altering the cells DNA. NanoScript ™ technology is multi-functional and synergistic for use with the Company's proprietary products to create any cell type including, but not limited to; muscle, cartilage, bone, adipocyte, neural and induced pluripotent cells (IPSCs) that are a genetic match for the donor. The Company believes that this technology, to induce differentiation without introducing a virus to the cell, provides the Company an opportunity to create a series of cellular therapy applications to treat chronic disease and traumatic injury, while at the same time overcoming certain genetic hurdles associated with generic cellular therapies.
"Rutgers University and Dr. Lee's extensive research experience with nanotechnology-inspired stem cell differentiation technologies, and their application of American CryoStem's proprietary ATCELL ™ and ACSelerate ™ products, have served to create a synergistic platform capable of dramatically increasing targeted point-of-care delivery of specific regenerative medicine therapies," stated Anthony Dudzinski, Chief Operating Officer of American CryoStem.
"Our collaboration with American CryoStem has allowed us to complete our ADSC-NanoScript technology platform and to advance our research to produce the repeatable results necessary for clinical development and FDA submission," stated Dr. Lee. Dr. Lee further stated "The ability to work with an FDA-registered laboratory with a unique and continuously expanding stem cell bank to ensure quality, uniformity and cellular purity is key to creating our master file for regulatory commercial product approval. The ATCELL ™ offering has greatly accelerated our platform technology which will be described in a forthcoming white paper detailing our ADSC-NanoScript research findings."
The initial focus of the Rutgers-American CryoStem collaboration has been on the regeneration of muscle cells for the repair of muscle loss from systemic disease and physical trauma, both of which are large, under-satisfied, medical needs without a repeatable cellular therapy solution. Further applications such as nerve repair for systemic disease and traumatic injuries, which markets the Company believes are underserved, are in the initial stages of development.
John S. Arnone, CEO of American CryoStem, noted "Rutgers' intellectual resources and extensive biotech research experience in the field of Regenerative Medicine, coupled with our Company's proprietary technologies and expertise with Adipose-Derived Stem Cells, has given rise to a powerful combination of intellectual property, skill, knowledge and common mission – to help accelerate the translation of stem cell-based therapies to the markets and the potential commercialization of exciting new stem cell therapies capable of effectively treating human illnesses and diseases."
American CryoStem continues to pursue the scientific advancement of multi-capable platforms with university-based research collaborations; and at the same time, growing its intellectual property pipeline while creating a wide range of cellular therapies and treatments for a growing number of challenging and underserved medical conditions and incurable diseases.
About KiBum Lee, PhD
Dr. Lee obtained his PhD in Chemistry from the Northwestern University and completed his postdoctoral research in stem cell biology at the Scripps Research Institute. His primary research interest ( http://chem.rutgers.edu/~kbleeweb/ ) is in developing and integrating nanotechnologies and chemical functional genomics to modulate signaling pathways in cells (e.g. stem cells and cancer cells) towards specific cell lineages or behaviors.
About American CryoStem Corporation
A biotechnology pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem operates a state-of-the-art, FDA-registered, clinical laboratory dedicated to processing, bio-banking and development of cellular applications using autologous adipose (fat) tissue and adipose derived stem cells (ADSCs). Through its scientific efforts, the Company has built a strong, strategic portfolio of intellectual property, patent applications, and proprietary operating processes that form its core standardized cellular platform. For more information, please visit www.americancryostem.com and www.acslaboratories.com . You can also find announcements and press releases on our corporate Facebook , Twitter , and LinkedIn profiles.
Forward Looking Statements
This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation's ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.
Investor Relations Contact: American CryoStem Corporation Office: 732-747-1007 www.americancryostem.com
